1. Introduction {#s0005}
===============

As the second most frequent infection disease worldwide, chronic periodontitis represents an infection-mediated inflammation whose hallmark is the destruction of the connective tissue that attaches the surface of teeth roots to alveolar bone. In addition, chronic periodontitis has also been related to lethal diseases, such as endocarditis, stroke, myocardial infarction and atherosclerosis ([@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025]).

The association between the presence of bacterial biofilm on teeth and oral mucosa surface ([@bb0030]) and periodontitis is clear. Besides, it is well known that environment factors, social habits, some drugs, systemic health and smoke influence the periodontitis prognosis. Likewise, a vast number of studies published in the last two decades have shown the importance of host genetic background as a key modulator of the response against the infection ([@bb0035], [@bb0045], [@bb0050], [@bb0055], [@bb0040]).

Suppressor Of Cytokine Signaling (SOCS) represents a family of signaling intracellular proteins that take part in the immune-system regulation, modulating the signal transduction of several inflammatory cytokines, including IL-1β. At least eight members of SOCS family have been described: SOCS1, SOCS2, SOCS3, SOCS4, SOCS5, SOCS6, SOCS7 and CIS ([@bb0060]). Addressing the role of SOCS1 to inflammation, its N-terminal domain contains inhibitory kinase-associated activity that strongly inhibits the JAK/STAT pathway (JAK (Janus kinase)/STAT (Signal Transducer and Activator of Transcription)) ([@bb0060], [@bb0065]). Recently, authors have reported that the TOLL-LIKE signaling may be modulated by SOCS1, affecting cell functions, cell differentiation and cell maturation [@bb0065].

*SOCS1* gene is a short sequence placed within chromosome 16. The coding sequence is composed by two exons that are regulated by a promoter region characterized by an extensive CpG island that covers the gene from its promoter until the end of the second exon. Downregulation of *SOCS1* has been observed in different types of cancer ([@bb0045], [@bb0075], [@bb0070]) and chronic inflammation ([@bb0080]). The macrophage deletion of *SOCS1* increased sensitivity to LPS in systemic inflammation ([@bb0085]). SOCS1 has been shown to play a potential role in modulating periodontitis ([@bb0090]) and it is down-regulated in chronic periodontitis when compared to chronic gingivitis ([@bb0050]). A number of genetic polymorphisms have been described within *SOCS1* gene. Two single nucleotide polymorphisms (SNP) placed at − 820 (rs33977706) and − 1478 (rs33989964) in the promoter region were shown to possess functional activity on gene transcription level. The SNP placed at − 820 creates the alleles C \> A and the presence of A allele disrupts a cis-consensus sequence to YY1 transcription factor binding, a negative regulator of *SOCS1* ([@bb0095]). Assay performed *in vitro* has demonstrated that A allele increases *SOCS1* mRNA levels ([@bb0095]). The *SOCS1*^− 1478^ SNP represents a dinucleotide CA insertion/deletion that has been associated with respiratory immune-inflammatory diseases ([@bb0010], [@bb0100]). There are no studies relating the functional role of *SOCS1* polymorphisms with the susceptibility or severity of periodontitis. Thus, the aim of the study was to investigate the relationship between these *SOCS1* polymorphisms with chronic periodontitis.

2. Material and methods {#s0010}
=======================

2.1. Ethics statement {#s0025}
---------------------

The study was performed in accordance with the current recommendations of the National Health Council---Ministry of Health of Brazil for research in human subjects and with the approval of the Ethics Committee in Research of the School of Dentistry of Piracicaba---State University of Campinas, Unicamp. Written informed consent was obtained from all volunteers.

2.2. Study population {#s0030}
---------------------

Subjects of both genders from the Southeastern region of Brazil were recruited from the patient pool of the Dental Clinics of the School of Dentistry of Piracicaba, State University of Campinas. Two hundred and fifty-seven (257) non-smoking subjects were included in this cross-sectional study and the demographic characteristics of the study population are presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}. All subjects were in good general health and had at least 20 teeth in their mouth. Subjects did not have any of the following exclusion criteria: smoking, diseases of the oral hard or soft tissues (except caries and periodontitis), use of orthodontic appliances, need for pre-medication for dental treatment, chronic usage of anti-inflammatory drugs, a history of diabetes, hepatitis or HIV infection, immunosuppressive chemotherapy, history of any disease known to severely compromise immune function, presence of acute necrotizing ulcerative gingivitis, or current pregnancy or lactation.

Diagnosis and classification of generalized chronic periodontitis were performed based on the 1999 Consensus Classification of Periodontal Diseases ([@bb0105]). The diagnostic examination considered the clinical parameters and consisted of physical examination, full medical and dental history, probing pocket depth (PPD), assessment of clinical attachment loss (CAL), tooth mobility and observation of gingival bleeding on probing and radiographic evaluation. Measurements of probing depth and attachment level were recorded at six points around each tooth. The individuals of the control group were examined attending the same clinical parameters as used in the chronic periodontitis group. Clinical parameters were obtained from one calibrated examiner (intra-class correlation = 0.94):

Control: Healthy subjects did not show any sites with CAL and PPD ≥ 3 mm and bleeding in any quadrant; tooth mobility was not found; age over 25 years.

Generalized Chronic Periodontitis (ChrP): Patients with at least 30% of the sites are affected with CAL ≥ 5 mm; age over 35 years.

Chronic Periodontitis subgroups:

Moderate Chronic Periodontitis (ChrP(M)): Patients with at least 30% of the sites are affected with CAL ≥ 5 mm and ≤ 7 mm; age over 35 years.

Severe Chronic Periodontitis ChrP(S): Patients with at least 30% of the sites are affected with CAL \> 7 mm; age over 35 years.

2.3. Isolation of genomic DNA {#s0035}
-----------------------------

DNA was collected from a mouthwash of oral cells as described by [@bb0110]. DNA was purified by the sequence of phenol/chloroform extraction and salt/ethanol precipitation. Following, DNA was dissolved in nuclease-free water and its concentration and quality were estimated by measuring absorbance at 280/260 nm and 280/230 nm, respectively (Nanodrop, Thermo).

2.4. Polymerase chain reaction (PCR) and genotyping (SNP − 820 (rs33977706)) {#s0040}
----------------------------------------------------------------------------

TaqMan System (Applied Biosystems by Life Technologies) was applied to investigate SOCS1^− 820^ polymorphism. PCRs were carried out in a total of 10 μl, containing: 100 ng of gDNA, 5 μl TaqMan Genotyping Master Mix, 0.5 μl TaqMan genotyping assay mix 20 × and H~2~O DNase-free. PCRs were performed in a LightCycler 480 (Roche) under the following conditions: 10′ at 95 °C, 40 × (15″ at 95°, 1′ at 60 °C). The VIC (HEX) (580 nm) discriminated the A allele while FAM (510 nm) discriminated the C allele.

2.5. Polymerase chain reaction (PCR) and genotyping (SNP − 1478 (rs33989964)) {#s0045}
-----------------------------------------------------------------------------

A fragment of 250 bp of the *SOCS1* gene promoter was PCR amplified with specific primer set ([Table 3](#t0015){ref-type="table"}). PCR was carried out in a total volume of 12 μl, containing 1 μl genomic DNA (100 ng), 1.5 μl of each primer and 6 μl of Go Taq Green Master Mix (Promega Corporation, Madison, WI, USA). The solution was incubated under the following conditions: 5 min. at 95 °C, 28 × (1′ at 95 °C, 1′ at 60 °C, 1′ at 72 °C), 7′ at 72 °C. The restriction endonuclease digestion was prepared using 3 μl aliquot of *SOCS1* PCR products mixed with solution containing 1 μl 10 × NE Buffer (50 mM NaCl, 10 mM Tris--HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9), 0.20 μl *DdE*I (10,000 U/ml) (New England Biolabs, Inc., Beverly, MA, USA) and 5.8 μl sterile deionized H~2~O. The solution was incubated at 37 °C overnight. The *DdE*I restriction endonuclease cuts the CA(+) allele, while the CA(−) allele does not. The length difference of the RFLP fragments was 145 bp and 105 bp (CA(−) 250 bp; CA(−)/CA(+) 250 bp, 145 bp and 105 bp; CA(+) 145 bp and 105 bp). Aliquots of 5 μl of the RFLP products were electrophoresed on 10% vertical non-denaturing polyacrylamide gel at 20 mA. Gels were stained using nucleic acid gel stain (SYBR Gold, Eugene, Oregon, USA).

2.6. Statistical analysis {#s0050}
-------------------------

We evaluated Hardy--Weinberg equilibrium (HWE), linkage disequilibrium, and haplotype frequency estimation using ARLEQUIN 3.0 software and HAPSTAT 3.0 software (The statistical analysis of haplotype-disease association, University of North Carolina at Chapel Hill) ([@bb0115], [@bb0120]). We also performed Chi-squared analysis in order to evaluate the genotype distribution and allele frequency in the groups using BIOESTAT 5.0 software (Instituto Mamiraua, Brazil) ([@bb0125]). A p-value of less than 5% was taken to be statistically significant for all analyses. We verified the statistical power of our sample using G\*POWER 3.0.5 software ([@bb0130]). The input parameters were: moderate effect size = 0.3, based on genotype distribution data; statistical significance level α = 0.05; and one and two degrees of freedom for allelic and genotype analysis, respectively. The statistical power for samples was higher than 80% for association detection.

3. Results {#s0015}
==========

Genotype distribution and allele frequency of *SOCS1*^− 1478^ and *SOCS1*^− 820^ SNPs were successfully performed in all subjects and the distribution of *SOCS1*^− 1478/− 820^ polymorphisms results were found in Hardy--Weinberg equilibrium in the studied groups (χ^2^, p \> 0.05). Significant differences were not found in genotypes and alleles distribution between groups for SOCS1^− 1478^ (χ^2^, p = 0.6959 and p = 0.4299, respectively) ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). The same was also observed for *SOCS1*^− 820^ genotype distribution (χ^2^, p = 0.1551) ([Fig. 1](#f0005){ref-type="fig"}). However, *SOCS1*^− 820^ result was seen bordering significance when alleles distribution was analyzed between controls and periodontitis group (χ^2^, p = 0.080) ([Fig. 2](#f0010){ref-type="fig"}), with an increase of C allele in periodontitis group. Then, we performed the next analysis for *SOCS1*^− 820^ separating the moderate chronic periodontitis samples (CAL ≤ 7 mm) from the severe chronic periodontitis samples (CAL \> 7 mm). Chronic periodontitis group was sub-classified into: moderate (ChrP(M) and severe (ChrP(S)). Performing analysis in control *versus* ChrP(M) *versus* ChrP(S), we observed a statistical significant difference in the genotype distribution between groups ((χ^2^, p \< 0.05) ([Fig. 3](#f0015){ref-type="fig"}). This significance became clearer when control was analyzed *versus* each ChrP subgroup. We noticed that SOCS1^− 820^ difference was came up from control *versus* ChrP(S) group, having significant differences for genotypes and alleles (χ^2^, p = 0.0309 and p = 0.0042, respectively) ([Fig. 4](#f0020){ref-type="fig"}). We clearly observed an increment of C allele within ChrP(S) followed a frequency decrease of A allele in the same group, probably due to the A allele protective effect against severe chronic periodontitis (OR = 0.3933; χ^2^, *p* = 0.0084, Bonferroni Correction, (IC95% 0.2112 \< μ \< 0.7324). In addition, analysis of *SOCS1*^− 820/− 1478^ haplotype revealed that the frequency of A^− 820^/CA^− 1478^ haplotype decreases in ChrP, having a statistically significant effect of this haplotype on ChrP (p = 0.0089) ([Fig. 5](#f0025){ref-type="fig"}).

4. Discussion {#s0020}
=============

The aim of this case--control study was to investigate the association between *SOCS1* genetic polymorphisms and chronic periodontitis. We observed association of *SOCS1*^− 820^ with severe chronic periodontitis cases, having lower frequency of A^− 820^ allele in the severe chronic periodontitis group, as well as decreased frequency of A^− 820^/CA^− 1478^ haplotype in chronic periodontitis group.

Chronic periodontitis is triggered by bacterial biofilm that covers teeth and soft tissues surfaces. Periodontal disease, once established, leads to a turnover imbalance between matrix extracellular components synthesis *versus* its destruction followed by periodontal tissue loss, including the Sharpey\'s fibers of collagen type I. The periodontitis prognosis will depend on the genetic background of host that will determinate the intensity of immune-inflammatory response against the infection.

The SOCS1 protein, also known as JAK binding protein-1 or STAT-induced STAT inhibitor-1, takes part in this environment. SOCS1 modulates the JAK-STAT intracellular signaling that represents a pathway used by a wide-range of pro-inflammatory cytokines. The target of SOCS1 is JAK kinase. The SOCS1--JAK association recruits ubiquitination enzymes that recognize and mark SOCS1--JAK complexes, activating the proteossomal system and leading to degradation of the complex; consequently, the STAT phosphorylation is inhibited as well its activation ([@bb0095]). Additionally, increasing evidences suggest that SOCS1 can also bind straightly to the cytokine receptor to trigger its degradation and/or mask the connection sites for adapting molecules. SOCS1 level is essential to regulate the action of some cytokines. Changes in the SOCS1 transcriptional activity may have important implication on the severity of inflammation.

*SOCS1* gene is found within chromosome 16. The transcription begins on the first exon; however, the coding sequence initiates on the second exon, where an Open Reading Frame (ORF) is found. Several genetic polymorphisms have been described all over *SOCS1* gene; the majority, apparently, is not functional.

Although we have not observed association between SOCS1^− 1478^ polymorphism and chronic periodontitis, [@bb0100] did show association between CA/CAdel heterozygous genotype and asthma in adults. The same authors observed an increased *SOCS1* promoter activity after they had performed luciferase report assay carrying on CA sequence. Another study investigated the association of SOCS1^− 1478^ polymorphism with Systemic Lupus Erythematosus (SLE) in DNA samples from subjects with serious clinical manifestations of SLE, such as thrombocytopenia and central nerve system (CNS) involvement. Authors found a higher frequency of SOCS1^− 1478del/del^ genotype in subjects with SLE and CNS involvement than those without CNS involvement ([@bb0010]).

For the best of our knowledge, this is the first study that reports an association of *SOCS1*^− 820^ polymorphism with chronic periodontitis. This polymorphism has also been described associated to obesity and insulin sensibility in Caucasians ([@bb0055]). Linkage disequilibrium is observed between *SOCS1*^− 820^ and *SOCS1*^+ 1125^ polymorphisms ([@bb0055]). The *SOCS1*^− 820^ was described as a functional polymorphism since A allele disrupts a promoter inhibitory site, potentiating the gene activity and promoting the increase o mRNA level. Performing *pGL3 basic* vector construction containing different inserts, some of which containing the − 820 region, an increased Luciferases activity was seen at the occurrence of the A allele ([@bb0095]). The same study demonstrated a higher expression of *SOCS1* associated to A/A and A/C genotypes when it was compared to C/C genotype ([@bb0095]). The increased promoter activity is thought to have occurred due to the disruption of a conserved DNA consensus sequence that binds to YY1 inhibitory transcription factor at the occurrence of A allele. Therefore, we suggest that the lower A allele frequency found in the severe chronic periodontitis group is due to the fact that A allele promotes protection against chronic periodontitis since A allele increases SOCS1 mRNA level and consequently SOCS1 protein level what promotes down-regulation of JAK/STAT pro-inflammatory pathway. It also explains the higher frequency of C/C genotype associated to chronic periodontitis group.

Although the A^− 820^/CA^− 1478^ haplotype was associated with control groups, the result must be a consequence of the protective effect of A allele on this haplotype, as previously the CAdel^− 1478^ allele was shown to increase SOCS1 promoter activity.

SOCS1 regulates the signaling of several pro-inflammatory cytokines. Among them, we highlight the signaling promoted by IL-6, IFN-1 and TNF-α, all of them highly transcribed during chronic periodontal inflammation ([@bb0050]). Therefore, the gene down regulation promoted by C allele created by SOCS1^− 820^ polymorphism can represent one of the risk factors addressed to periodontitis severity while A allele plays a protective role during periodontitis.
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![The genotypes frequencies of SOCS1^− 820/− 1478^ polymorphisms in Control and ChrP groups. Significant differences were not found for genotype distribution of both polymorphisms in groups.](gr1){#f0005}

![The alleles frequencies of SOCS1^− 820/− 1478^ polymorphisms in Control and ChrP groups. Significant difference was not found for SOCS1^− 1478^ allele frequency in groups.](gr2){#f0010}

![Genotype frequency of SOCS1^− 820^ in Control, ChrP(M) and ChrP(S) groups. Significant difference was found when ChrP samples were sub-classified into ChrP(M) and ChrP(S) groups. (χ^2^, p = 0.10, Bonferroni correction.)](gr3){#f0015}

![Genotype and allele frequency of SOCS1^− 820^ in Control and ChrP(S) groups. The significant differences are greater when control allele result was plotted against ChrP(S) results. (χ^2^, p = 0.0618 and p = 0.0084, Bonferroni correction.)](gr4){#f0020}

![Haplotype frequency of SOCS1^− 820/− 1478^ in Control and ChrP(S) groups. The decrease frequency of A^− 820^/CA^− 1478^ polymorphisms in ChrP group impacts significantly the disease.](gr5){#f0025}

###### 

*SOCS1*^− 820\ locus^: sample demographic dataset.

  *SOCS1*^− 820^      Age     Gender   Ancestry (%)                 
  ------------------- ------- -------- -------------- ---- --- ---- ---
  Control (N = 105)   37.28   38.78%   61.22%         82   1   9    8
  ChrP(M) (N = 86)    45.06   35.94%   64.06%         72   0   19   8
  ChrP(S) (N = 51)    44.78   28.21%   71.79%         67   0   28   5

C---Caucasian; J---Japanese; M---Mulatto; AA---Afro-American.

Control---Healthy; ChrP(M)---Moderate Chronic Periodontitis; ChrP(S)---Severe Chronic Periodontitis.

###### 

SOCS1^− 1478\ locus^: sample demographic dataset.

  SOCS1^− 1478^       Age     Gender   Ancestry (%)                 
  ------------------- ------- -------- -------------- ---- --- ---- ---
  Control (N = 111)   37.27   37.86%   61.17%         82   1   9    8
  ChrP(M) (N = 90)    45.95   33.85%   66.15%         76   0   16   8
  ChrP(S) (N = 56)    44.95   26.83%   73.17%         68   0   27   5

C---Caucasian; J---Japanese; M---Mulatto; AA---Afro-American.

Control---Healthy; ChrP(M)---Moderate Chronic Periodontitis; ChrP(S)---Severe Chronic Periodontitis.

###### 

SOCS1^− 1478^ primers set, amplicon size, and restriction endonuclease site.

  ------------------------------------------------------------
  Primer                       Amplicon   Restriction enzyme
  ---------------------------- ---------- --------------------
  FOW---TGTCGTCCAGCTGCACCTC    250pb      **DdEI**\
                                          C↓TNAG...3′\
                                          GANT↓C...5′

  REV---ACCACAGGCTTCAGAGGAAC              
  ------------------------------------------------------------

[^1]: These authors contributed equally to the study.
